Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Hikma Pharms Plc S/Adr (OP:HKMPY)

45.06 +0.44 (+0.99%)
Streaming Delayed Price Updated: 3:31 PM EST, Feb 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 372
Open 45.06
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 44.62
Today's Range 45.06 - 45.06
52wk Range 39.93 - 56.94
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Hikma announces Health Canada approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg
Emergent BioSolutions will lead commercial launch efforts to increase access to intranasal naloxone and combat opioid overdose poisonings in Canada 
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Shortage Relief: More Takeda's Vyvanse For ADHD On the Way As US Ramps Up Production ↗
Increase in production of Takeda's ADHD drug Vyvanse, approved by DEA to address ongoing shortages both domestically and globally. 
Via Benzinga

Performance

YTD
+8.0%
+8.0%
1 Month
+2.6%
+2.6%
3 Month
+7.9%
+7.9%
6 Month
-9.2%
-9.2%
1 Year
-17.8%
-17.8%

More News

Read More
News headline image
Jazz And Hikma Accused Of Delaying Sleep Disorder Generic Drug To Maintain High Prices ↗
Via Benzinga
News headline image
Guardant Health and Hikma Partner to Offer Cancer Screening and Comprehensive Genomic Profiling Tests in the Middle East and North Africa
From Guardant Health, Inc.
Via Business Wire
News headline image
Drug Shortages in Focus: How FDA's Quest for New Methotrexate Suppliers Affects the Cancer Treatment Landscape ↗
Via Benzinga
News headline image
Junshi Biosciences and Hikma Sign Exclusive Licensing Agreement for Cancer Treatment Drug Toripalimab for the Middle East and North Africa Region
From Junshi Biosciences
Via GlobeNewswire
News headline image
Friday Markets News ↗
Via Talk Markets
News headline image
Bio-Thera Solutions and Hikma Pharmaceuticals Announce Exclusive Commercialization and License Agreement for BAT2206 in the US, a Proposed Biosimilar Referencing Stelara® (ustekinumab)
From Bio-Thera Solutions, Ltd.
Via Business Wire
News headline image
Summer Friday ↗
Via Talk Markets

Frequently Asked Questions

Is Hikma Pharms Plc S/Adr publicly traded?
Yes, Hikma Pharms Plc S/Adr is publicly traded.
What exchange does Hikma Pharms Plc S/Adr trade on?
Hikma Pharms Plc S/Adr trades on the OTC Traded
What is the ticker symbol for Hikma Pharms Plc S/Adr?
The ticker symbol for Hikma Pharms Plc S/Adr is HKMPY on the OTC Traded
What is the current price of Hikma Pharms Plc S/Adr?
The current price of Hikma Pharms Plc S/Adr is 45.06
When was Hikma Pharms Plc S/Adr last traded?
The last trade of Hikma Pharms Plc S/Adr was at 02/25/26 03:31 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.